UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Body-Weight Fluctuations and Outcomes in Coronary Disease

The New England journal of medicine, 2017-04, Vol.376 (14), p.1332-1340

2017

Volltextzugriff (PDF)

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack

Journal of the American College of Cardiology, 2017-01, Vol.69 (2), p.147-158

2017

Volltextzugriff (PDF)

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

The American journal of medicine, 2014, Vol.127 (1), p.71-81.e1

2014

Volltextzugriff (PDF)

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

The American journal of medicine, 2016-04, Vol.129 (4), p.384-391

2016

Volltextzugriff (PDF)

Visit-to-visit variability of lipid measurements as predictors of cardiovascular events

Journal of clinical lipidology, 2018-03, Vol.12 (2), p.356-366

2018

Volltextzugriff (PDF)

Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials

The American journal of cardiology, 2015-02, Vol.115 (4), p.447-453

2015

Volltextzugriff (PDF)

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Heart (British Cardiac Society), 2015-03, Vol.101 (5), p.356-362

2015

Volltextzugriff (PDF)

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

The American journal of cardiology, 2014-06, Vol.113 (12), p.2018-2020

2014

Volltextzugriff (PDF)

Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non – Pre-Diabetics

Journal of the American College of Cardiology, 2015-02, Vol.65 (4), p.402-404

2015

Volltextzugriff (PDF)

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial

Drugs & aging, 2015-12, Vol.32 (12), p.1055-1065

2015

Volltextzugriff (PDF)

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients with Coronary Artery Disease (From the Treating to New Targets [TNT] Study)

The American journal of cardiology, 2016-08, Vol.118 (4), p.494-498

2016

Volltextzugriff (PDF)

Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy

Journal of the American College of Cardiology, 2015-04, Vol.65 (13), p.1286-1295

2015

Volltextzugriff (PDF)

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories

Journal of the American College of Cardiology, 2020-05, Vol.75 (17), p.2110-2118

2020

Volltextzugriff (PDF)

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial

Journal of the American College of Cardiology, 2020-05, Vol.75 (17), p.2110-2118

2020

Volltextzugriff (PDF)

Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial

The American journal of cardiology, 2017-02, Vol.119 (3), p.379-387

2017

Volltextzugriff (PDF)

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

International journal of cardiology, 2013-10, Vol.168 (4), p.3846-3852

2013

Volltextzugriff (PDF)

ATORVASTATIN REDUCES TOTAL EVENTS OVERALL AND ACROSS VASCULAR BEDS IN THE SPARCL TRIAL

Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.2202-2202

2020

Volltextzugriff (PDF)

Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial

Journal of the American College of Cardiology, 2015-04, Vol.65 (13), p.1286-1295

2015

Volltextzugriff (PDF)

Ion channels and regulation of intracellular calcium in vascular endothelial cells

The FASEB journal, 1989-10, Vol.3 (12), p.2389-2400

1989

Volltextzugriff (PDF)

Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT and IDEAL

Journal of the American College of Cardiology, 2015-02, Vol.65 (4), p.402-404

2015

Volltextzugriff (PDF)

Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis

Clinical drug investigation, 2017-08, Vol.37 (8), p.775-785

2017

Volltextzugriff (PDF)

ELEVATED LEVELS OF OXIDIZED PHOSPHOLIPIDS ON APOLIPOPROTEIN B-100 PREDICT RECURRENT CEREBROVASCULAR EVENTS: A STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS (SPARCL) SUBSTUDY

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A1374-A1374

2015

Volltextzugriff (PDF)

RISK OF NEW-ONSET DIABETES FROM STATIN THERAPY INCREASES WITH INCREASING BASELINE TRIGLYCERIDES: DATA FROM TNT

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A1441-A1441

2015

Volltextzugriff (PDF)

2013 ACC/AHA GUIDELINE RECOMMENDATION ON BLOOD CHOLESTEROL REVISITED: PERCENT LDL-C REDUCTION OR ATTAINED LDL-C LEVEL OR BOTH FOR PROGNOSIS?

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A1361-A1361

2015

Volltextzugriff (PDF)

ANALYSIS OF SAFETY OF ATORVASTATIN IN ASIAN PATIENTS IN CLINICAL TRIALS

Heart (British Cardiac Society), 2012-10, Vol.98 (Suppl 2), p.E316-E316

2012

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(59)

Publikationsform

Sprache

Englisch
(69)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Body-Weight Fluctuations and Outcomes in Coronary Disease

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

Visit-to-visit variability of lipid measurements as predictors of cardiovascular events

Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials

High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non – Pre-Diabetics

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial

Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients with Coronary Artery Disease (From the Treating to New Targets [TNT] Study)

Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories

Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial

Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

ATORVASTATIN REDUCES TOTAL EVENTS OVERALL AND ACROSS VASCULAR BEDS IN THE SPARCL TRIAL

Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial

Ion channels and regulation of intracellular calcium in vascular endothelial cells

Risk of New-Onset Diabetes and Cardiovascular Risk Reduction From High-Dose Statin Therapy in Pre-Diabetics and Non–Pre-Diabetics: An Analysis From TNT and IDEAL

Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis

ELEVATED LEVELS OF OXIDIZED PHOSPHOLIPIDS ON APOLIPOPROTEIN B-100 PREDICT RECURRENT CEREBROVASCULAR EVENTS: A STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS (SPARCL) SUBSTUDY

RISK OF NEW-ONSET DIABETES FROM STATIN THERAPY INCREASES WITH INCREASING BASELINE TRIGLYCERIDES: DATA FROM TNT

2013 ACC/AHA GUIDELINE RECOMMENDATION ON BLOOD CHOLESTEROL REVISITED: PERCENT LDL-C REDUCTION OR ATTAINED LDL-C LEVEL OR BOTH FOR PROGNOSIS?

ANALYSIS OF SAFETY OF ATORVASTATIN IN ASIAN PATIENTS IN CLINICAL TRIALS

Suchergebnisse filtern